Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) EPS (Weighted Average and Diluted) (2018 - 2025)

Marimed (MRMD) has disclosed EPS (Weighted Average and Diluted) for 8 consecutive years, with -$0.01 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 284.44% to -$0.01 in Q3 2025 year-over-year; TTM through Sep 2025 was -$0.04, a 0.0% change, with the full-year FY2024 number at -$0.03, up 25.0% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.01 for Q3 2025 at Marimed, down from -$0.0 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.02 in Q4 2022 to a low of -$0.03 in Q4 2023.
  • A 5-year average of -$0.0 and a median of -$0.0 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 521.76% in 2021, then crashed 286.38% in 2024.
  • Marimed's EPS (Weighted Average and Diluted) stood at -$0.02 in 2021, then surged by 200.0% to $0.02 in 2022, then crashed by 250.0% to -$0.03 in 2023, then soared by 33.33% to -$0.02 in 2024, then skyrocketed by 50.0% to -$0.01 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's EPS (Weighted Average and Diluted) are -$0.01 (Q3 2025), -$0.0 (Q2 2025), and -$0.01 (Q1 2025).